Efficacy and safety of neratinib and capecitabine in HER2 positive metastatic breast cancer: a systematic review

被引：0
|
作者：
Mokalu, E. Wilhelmina [1 ]
Sabran, M. Zuhriansyah [1 ]
Yossy, P. [1 ]
Rubismo, K. Yogasvara [1 ]
Zebua, A. [1 ]
Albert, N. [1 ]
Hasan, J. Irisha Xenia [1 ]
Kurniawan, A. [2 ]
机构：
[1] Univ Pelita Harapan, Fac Med, Tangerang, Indonesia
[2] Univ Pelita Harapan, Dept Internal Med, Fac Med, Tangerang, Indonesia
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.07.472
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P90-6
引用
收藏
页码：S1393 / S1393
页数：1
相关论文
共 50 条
  • [31] Manageable treatment with lapatinib and continuous metronomic capecitabine in HER2 positive advanced breast cancer (ABC): Efficacy and safety data.
    Orlando, Laura
    Lutrino, Stefania Eufemia
    Fontanella, Caterina
    Quaranta, Annamaria
    Caliolo, Chiara
    Cinefra, Margherita
    Schiavone, Paola
    Fedele, Palma
    Calvani, Nicola
    Mazzoni, Enrica
    Marino, Antonella
    Rizzo, Pietro
    Nacci, Angelo
    D'amico, Maria
    Sponziello, Francesco
    Ferrara, Pasqualinda
    Caloro, Manuela
    Caforio, Cosimo
    Sordi, Emiliano
    Cinieri, Saverio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Systematic Review of HER2 Breast Cancer Testing
    Cuadros, Marta
    Villegas, Roman
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2009, 17 (01) : 1 - 7
  • [33] Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
    Murthy, R. K.
    Loi, S.
    Okines, A.
    Paplomata, E.
    Hamilton, E.
    Hurvitz, S. A.
    Lin, N. U.
    Borges, V.
    Abramson, V.
    Anders, C.
    Bedard, P. L.
    Oliveira, M.
    Jakobsen, E.
    Bachelot, T.
    Shachar, S. S.
    Mueller, V.
    Braga, S.
    Duhoux, F. P.
    Greil, R.
    Cameron, D.
    Carey, L. A.
    Curigliano, G.
    Gelmon, K.
    Hortobagyi, G.
    Krop, I.
    Loibl, S.
    Pegram, M.
    Slamon, D.
    Palanca-Wessels, M. C.
    Walker, L.
    Feng, W.
    Winer, E. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07): : 597 - 609
  • [34] Trastuzumab deruxtecan, its efficacy in patients with metastatic HER2-positive breast cancer: a systematic review
    Fernhandho, V.
    Jhoputri, C. Fricilia
    Julian, L.
    Kurniawan, A.
    Huang, I.
    ANNALS OF ONCOLOGY, 2024, 35 : S1337 - S1337
  • [35] TRASTUZUMAB EMTANSINE FOR HER2 POSITIVE BREAST CANCER PATIENTS: AN UPDATED SYSTEMATIC REVIEW
    Valle, P. M.
    Mosegui, G. B.
    Vianna, C. M.
    Araujo, R. L.
    Felicissimo, T.
    Lima, I. J.
    VALUE IN HEALTH, 2015, 18 (07) : A816 - A816
  • [36] Phase II Study of Neratinib and Trastuzumab plus -oral Vinorelbine in previously treated metastatic Her2 positive Breast Cancer
    Balic, M.
    Posch, F.
    Bartsch, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 106 - 106
  • [37] Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience
    Omarini, C.
    Medici, G.
    Guaitoli, G.
    Iattoni, E.
    Moscetti, L.
    Balduzzi, S.
    Cascinu, S.
    Piacentini, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] Issues and controversies in the treatment of HER2 positive metastatic breast cancer
    Amar, Surabhi
    Moreno-Aspitia, Alvaro
    Perez, Edith A.
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (01) : 1 - 7
  • [39] Issues and controversies in the treatment of HER2 positive metastatic breast cancer
    Surabhi Amar
    Alvaro Moreno-Aspitia
    Edith A. Perez
    Breast Cancer Research and Treatment, 2008, 109 : 1 - 7
  • [40] Outcome of non-metastatic HER2 positive breast cancer
    Mehmood, T.
    Rashid, A.
    Irfan, N.
    Hameed, S.
    Shah, M. Ali
    Jamshed, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S54 - S54
12345